Auvi-q Injection, Solution
NDC Package 51662-1663-2
Package Information
Auvi-q injection is a medication used in emergencies to treat very serious allergic reactions to insect stings/bites, foods, drugs, or other substances. This formulation utilizes a injection, solution delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1663 and is authorized under FDA application NDA201739.
Identification & Billing
- RxCUI: 1870205 - EPINEPHrine (generic for Auvi-Q) 0.3 MG in 0.3 ML Auto-Injector
- RxCUI: 1870205 - NDA201739 0.3 ML epinephrine 1 MG/ML Auto-Injector
- RxCUI: 1870205 - epinephrine (generic for Auvi-Q) 0.3 MG per 0.3 ML Auto-Injector
Clinical Specifications
- Adrenergic alpha-Agonists - [MoA] (Mechanism of Action)
- Adrenergic beta-Agonists - [MoA] (Mechanism of Action)
- Catecholamine - [EPC] (Established Pharmacologic Class)
- Catecholamines - [CS]
- alpha-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
- beta-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 51662 - Hf Acquisition Co Llc, Dba Healthfirst
- 51662-1663 - Auvi-q
- 51662-1663-2 - 2 DOSE PACK in 1 CARTON / .3 mL in 1 DOSE PACK (51662-1663-1)
- 51662-1663 - Auvi-q
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51662-1663-2 identifies a specific commercial package of 2 dose pack in 1 carton / .3 ml in 1 dose pack (51662-1663-1) of Auvi-q, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This injection, solution is formulated for intramuscular use and contains epinephrine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on November 15, 2012. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used in emergencies to treat very serious allergic reactions to insect stings/bites, foods, drugs, or other substances. Epinephrine acts quickly to improve breathing, stimulate the heart, raise a dropping blood pressure, reverse hives, and reduce swelling of the face, lips, and throat.
How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662166302. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.